Yin Zhu

Yin Zhu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
XLXue-Yang Li
Xue-Yang Li
CHCong He
Cong He
YZYin Zhu
Yin Zhu
NLNong-Hua Lu
Nong-Hua Lu
Role of gut microbiota on intestinal barrier function in acute pancreatitis

12 June 2020 in Gut Microbes
Verified
Journal Article
Closed access
XLXueyang Li
Xueyang Li
CHCong He
Cong He
NLNianshuang Li
Nianshuang Li
LDLing Ding
Ling Ding
HCHongyan Chen
Hongyan Chen
NLNonghua Lu
Nonghua Lu
Early dysbiosis of the gut microbiota is associated with the severity of acute pancreatitis (AP), although the underlying mechanism is unclear. Here, we investigated the role of crosstalk between NLRP3 and the gut microbiota in the development of AP utilizing gut microbiota deficient mice, as well as NLRP3 knockout (KO) mouse models. Pancreatic damage and systemic inflammation were improved in antibiotic-treated (Abx) and germ-free (GF) mice, accompanied by weakened activity of the intestinal NLRP3 inflammasome. Interestingly, fecal microbiota transplantation (FMT) reactivated the intestinal NLRP3 inflammasome and exacerbated the disease in Abx and GF mice. Although the gut barrier in GF and Abx mice was disrupted, gut microbiota deficiency ameliorated the severity of AP, probably due to the reduction in bacterial translocation from the gut to the pancreas. The composition of the gut microbiota was significantly different between NLRP3 KO mice and wild-type (WT) mice at baseline, and there were alterations in response to the induction of AP. While a dramatic shift in the gut microbiota with overgrowth of Escherichia-Shigella was observed in WT mice suffering from AP, there was no significant change in NLRP3 KO mice with or without AP, suggesting that NLRP3 deficiency counteracts AP-induced microbial disturbance. With a strengthened gut barrier and decreased systemic inflammation, NLRP3 KO mice showed less severe AP, as revealed by reduced pancreatic neutrophilic infiltration and necrosis. Taken together, these results identified the bidirectional modulation between the gut microbiota and NLRP3 in the progression of AP, which suggests the interplay of the host and microbiome during AP.

5 May 2017 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
YHYi Hu
Yi Hu
YZYin Zhu
Yin Zhu
NLNonghua Lu
Nonghua Lu
Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. H. pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth–containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility–based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan–containing triple therapies, quintuple therapies, high–dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

16 October 2021 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
YZYanan Zhou
Yanan Zhou
YFYating Fan
Yating Fan
RCRui Cao
Rui Cao
YXYingying Xu
Yingying Xu
XWXiaolei Wang
Xiaolei Wang

11 September 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
YHY. Hu
Y. Hu
JWJ.‐H. Wan
J.‐H. Wan
XLX.‐Y. Li
X.‐Y. Li
YZYin Zhu
Yin Zhu
DGDavid Graham
David Graham
NLN.‐H. Lu
N.‐H. Lu

22 November 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NLNianshuang Li
Nianshuang Li
YFYan Feng
Yan Feng
YHYi Hu
Yi Hu
CHcong he
cong he
CXChuan Xie
Chuan Xie
NLNonghua Lu
Nonghua Lu
Background: Helicobacter pylori (H. pylori) delivers oncoprotein CagA into gastric epithelial cells via the T4SS and drives activation of multiple oncogenic signalling pathways. YAP, a core effector of the Hippo tumour suppressor pathway, is frequently overexpressed in human cancers, suggesting its potential tumor-promoting role. Although CagA is a casual factor in H. pylori induced gastric carcinogenesis, the link between CagA and YAP pathway has not been identified. In this work, we investigated the regulation of oncogenic YAP pathway by H. pylori CagA. Methods: Expression of YAP and E-cadherin protein in human gastric biopsies were assessed by immunohistochemistry. H. pylori PMSS1 cagA− isogenic mutant strains were generated. Gastric epithelial cells were co-cultured with H. pylori wild-type cagA+ strains or isogenic mutants and were also treated by recombinant CagA expression. Immunofluorescence was performed for YAP localization. Immunoblot and quantitative PCR were performed for examining levels of YAP, downstream effectors and markers of epithelial-mesenchymal transition. Verteporfin and siRNA silencing were used to inhibit YAP activity. Results: YAP is significantly upregulated in human gastric carcinogenesis. We generated PMSS1 CagA isogenic mutant strains with chloramphenicol resistance successfully. Our analysis indicated that H. pylori infection induced YAP and downstream effectors in gastric epithelial cells. Importantly, knockout of CagA in 7.13 and PMSS1 strains reduced the expression of YAP by H. pylori infection. Moreover, Inhibition of YAP suppressed H. pylori infection-induced Epithelial-mesenchymal transition (EMT). Conclusion: Our results indicated that H. pylori CagA as a pathogenic protein promotes oncogenic YAP pathway, which contributes to EMT and gastric tumorigenesis. This study provided a novel mechanistic insight into why cagA+H. pylori infection is associated with a higher risk for the development of gastric cancer.